Rafael Holdings Announced Submission of New Drug Application to FDA for Trappsol®Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C
Rafael Holdings, Inc. (NYSE: RFL) announced on Oct. 29 that its subsidiary, Cyclo Therapeutics, LLC, has submitted a New Drug
